Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rallybio Corporaton
(NQ:
RLYB
)
1.770
-0.090 (-4.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rallybio Corporaton
< Previous
1
2
3
Next >
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
May 07, 2024
From
Rallybio Corporation
Via
Business Wire
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
April 17, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
April 10, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
April 01, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
February 06, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
January 04, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
December 20, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
December 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
November 28, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
November 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
October 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
September 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
July 11, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
June 29, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
June 24, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
June 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports First Quarter 2023 Financial Results
May 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
May 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
April 06, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
April 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Rallybio Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.